Literature DB >> 8702568

The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors.

F Claessens1, P Alen, A Devos, B Peeters, G Verhoeven, W Rombauts.   

Abstract

The nuclear receptors constitute a large family of transcription factors characterized by a well conserved DNA-binding domain. The receptors for glucocorticoids, progestins, mineralocorticoids, and androgens constitute a subgroup because they bind in vitro with high affinity to DNA elements containing a partial palindrome of the core sequence 5'-TGTTCT-3'. In vivo, however, the corresponding steroids differentially regulate the expression of their target genes, even when more than one receptor type is present in a particular cell. The DNA-binding domains of the androgen and of the glucocorticoid receptors bind most androgen response elements with similar relative affinities. In contrast, one element (5'-GGTTCTTGGAGTACT-3') which was recently described in the promoter region of the probasin gene selectively interacts with the DNA-binding domain of the androgen receptor and not with that of the glucocorticoid receptor. From studies with chimeric elements, it can be deduced that it is the left subsequence 5'-GGTTCT-3' which excludes the glucocorticoid receptor domain from binding. In co-transfection experiments where the ARE of the C3(1) gene is responsive to both androgens and glucocorticoids, the probasin element is induced only by androgens and not by glucocorticoids. The existence of response elements which are recognized preferentially by the androgen receptor provides yet another possible mechanism to explain the differences of the in vivo effects between androgens and other steroids of the subgroup.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702568     DOI: 10.1074/jbc.271.32.19013

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains.

Authors:  E Schoenmakers; P Alen; G Verrijdt; B Peeters; G Verhoeven; W Rombauts; F Claessens
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

2.  FHL2, a novel tissue-specific coactivator of the androgen receptor.

Authors:  J M Müller; U Isele; E Metzger; A Rempel; M Moser; A Pscherer; T Breyer; C Holubarsch; R Buettner; R Schüle
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

3.  DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation.

Authors:  Annemie Haelens; Guy Verrijdt; Leen Callewaert; Valerie Christiaens; Kris Schauwaers; Ben Peeters; Wilfried Rombauts; Frank Claessens
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

4.  I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor.

Authors:  S Heck; K Bender; M Kullmann; M Göttlicher; P Herrlich; A C Cato
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

Review 5.  New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Authors:  Margaret M Centenera; Luke A Selth; Esmaeil Ebrahimie; Lisa M Butler; Wayne D Tilley
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

Review 6.  The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications.

Authors:  Amy B Cadwallader; Carol S Lim; Douglas E Rollins; Francesco Botrè
Journal:  J Anal Toxicol       Date:  2011-11       Impact factor: 3.367

7.  Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor.

Authors:  Sara H Windahl; René Galien; Riccardo Chiusaroli; Philippe Clément-Lacroix; Frederic Morvan; Liên Lepescheux; François Nique; William C Horne; Michèle Resche-Rigon; Roland Baron
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

8.  Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription.

Authors:  Keiko Hosohata; Peng Li; Yoshiaki Hosohata; Jun Qin; Robert G Roeder; Zhengxin Wang
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.

Authors:  W Zhai; Y Sun; M Jiang; M Wang; T A Gasiewicz; J Zheng; C Chang
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

10.  Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.

Authors:  D Alwyn Dart; Bradley Spencer-Dene; Simon C Gamble; Jonathan Waxman; Charlotte L Bevan
Journal:  Endocr Relat Cancer       Date:  2009-07-27       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.